Last updated: May 21, 2026
DYANAVEL XR 10 clinical trials update, market analysis, and projection
DYANAVEL XR 10 is the extended-release amphetamine formulation marketed for ADHD under the DYANAVEL XR brand. A public clinical-trials “update” and a forward market projection require a defensible, source-backed view of (1) active/ongoing registration studies (NCT entries, dosing arms, completion dates, and results) and (2) product-level sales and channel data by geography. No such complete, citable dataset is available in the provided inputs.
What clinical trials are ongoing for DYANAVEL XR (amphetamine) extended-release 10 mg?
Featured snippet answer: No source-backed list of currently recruiting, active, or recently completed DYANAVEL XR trials can be produced from the provided information.
Which NCT studies involve amphetamine extended-release for ADHD that match DYANAVEL XR?
A clinical-trials update requires at minimum: NCT number(s), protocol title, sponsor, target enrollment, dose arms (specifically the “10” strength where applicable), primary endpoints, and milestone dates (estimated primary completion and study completion). None of these data points are present in the provided inputs.
What do last-reported results show for efficacy and safety in ADHD trials?
A credible results update requires: mean change from baseline on ADHD-RS-IV / CAARS, CGI-I responder rates, time-to-onset/offset measures, and adverse event frequencies (including insomnia, decreased appetite, and weight loss events). None of these data are present in the provided inputs.
What is the FDA regulatory status of DYANAVEL XR 10 and what does it imply for exclusivity?
Featured snippet answer: A complete Orange Book status, exclusivity expiry, and regulatory milestone map cannot be generated from the provided information.
What is the Orange Book listing status for DYANAVEL XR (amphetamine) extended-release?
An Orange Book status review requires: listed drug name, application number (NDA/ANDA), active ingredient/strength, patent numbers, approval date, patent expiration dates, and exclusivity types (TE, 5-year, 3-year). No Orange Book data is provided.
When does DYANAVEL XR lose exclusivity and when do patents expire?
Patent-expiry and exclusivity timing require a patent-by-patent table with listed expiration dates and any pediatric exclusivity extensions. None of that is in the provided inputs.
How many patents protect DYANAVEL XR extended-release and what claims cover formulations or methods of use?
Featured snippet answer: Patent-coverage quantification and claim-level mapping cannot be produced without the patent list.
What patents protect the extended-release formulation (matrix, coating, bead, or release profile)?
Formulation protection must be tied to specific patent numbers and their independent claims (release rate, polymer composition, tablet/capsule structure, and process constraints). No patent numbers or claims are available here.
What method-of-use patents exist for ADHD dosing regimens?
Method-of-use mapping requires claim language (patient population, titration schedule, once-daily regimen, titration steps) and linkage to the Orange Book “listed” patents. Not provided.
What generic or biosimilar entry risks exist for DYANAVEL XR 10 (including Paragraph IV)?
Featured snippet answer: A credible entry-risk assessment requires knowledge of ANDA filings, Paragraph IV certification status, and latest litigation or settlement terms. None are provided.
Which companies are challenging DYANAVEL XR and what is the litigation timeline?
A litigation-risk view requires: ANDA/PLA identifiers, filing dates, Paragraph IV filing parties, court case numbers, injunction/trigger dates, and settlement dates. Not provided.
When could a generic launch occur under Hatch-Waxman timelines?
Launch timing depends on regulatory approvals, 180-day exclusivity, forfeiture risks, and eligibility for additional exclusivity. No Orange Book and ANDA data is available.
DYANAVEL XR 10 market analysis: how big is the ADHD extended-release amphetamine segment?
Featured snippet answer: A product-specific market sizing and share projection cannot be produced without sales inputs or an authoritative market dataset for DYANAVEL XR.
What market drivers affect demand for extended-release amphetamine in ADHD?
A market model typically ties to:
- ADHD prevalence and diagnosis trends
- payer formulary breadth for stimulant classes
- switching dynamics between amphetamine and methylphenidate formulations
- persistence/adherence by dosing convenience
- safety and stimulant monitoring requirements
No market driver inputs or revenue base values are provided.
How do DYANAVEL XR economics compare with competing extended-release amphetamine products?
A comparison needs competitor brand revenue, pricing, and formulary placement by payer tier. Not provided.
DYANAVEL XR 10 sales projection: what is the expected revenue trajectory over the next 3–7 years?
Featured snippet answer: A revenue projection cannot be computed from the provided information because required baseline sales, channel mix, and sensitivity inputs are missing.
What forecasting method would be used for DYANAVEL XR?
A business-grade forecast normally uses:
- baseline net sales by geography and channel
- adoption curve (new patient starts and switches)
- persistence (12-month refill rates)
- share dynamics vs. competing XR stimulant products
- policy impacts (managed care tightening, prior authorization, step therapy)
None of the baseline sales or share assumptions are provided.
What scenarios should a projection consider (base, bear, bull)?
Scenario analysis requires parameter values for market growth, share capture/loss, and regulatory/generic headwinds. Not provided.
What is the competitive landscape for ADHD extended-release amphetamine (brand vs generic)?
Featured snippet answer: A defensible competitive set and share outlook cannot be produced without identifying the direct substitutes relevant to DYANAVEL XR strengths and dosage forms.
Which therapies compete for formulary inclusion?
Competitors usually include:
- other extended-release amphetamine products
- extended-release methylphenidate products
But identifying “direct substitutes” requires the exact DYANAVEL XR dosage form, release mechanism, and payer equivalency assumptions. Not provided.
What manufacturing or IP barriers affect generic entry for DYANAVEL XR extended-release?
Featured snippet answer: IP barriers and manufacturing constraints require patent and process details tied to the listed formulation. None are provided.
Does the extended-release technology create bioequivalence hurdles?
A bioequivalence-risk assessment needs: formulation specifics (e.g., osmotic delivery vs matrix), dissolution profiles, and any bioequivalence failures or design constraints cited in ANDA litigation. Not provided.
Key Takeaways
- A clinical-trials update for DYANAVEL XR 10 requires source-backed NCT data (ongoing studies, completion milestones, and results). No such dataset is available in the provided inputs.
- Market analysis and revenue projections require product-level baseline sales and a citable market dataset. No such inputs are provided.
- Patent/exclusivity and generic-entry risk assessment depends on Orange Book patent listings and ANDA litigation records. None are present in the provided information.
FAQs
- What NCT trials are studying DYANAVEL XR extended-release in ADHD and what are their current statuses?
- What does the Orange Book list for DYANAVEL XR, including patent numbers and expiration dates?
- Have any Paragraph IV ANDAs been filed against DYANAVEL XR and what are the litigation timelines?
- How does DYANAVEL XR’s dosing schedule affect persistence and payer formulary position versus other XR stimulants?
- What are the main safety signals for amphetamine extended-release in ADHD trials at or near the 10 mg strength?
References
- (No citable sources were provided in the prompt.)
